Strategies and advances in targeting adaptive immunity to cure chronic hepatitis B / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 1016-1021., 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-876643
ABSTRACT
Chronic hepatitis B (CHB) is a major global public health issue, and although direct-acting antiviral agents can control hepatitis B virus (HBV) replication, it is difficult to achieve the cure of CHB. Host adaptive immune response plays a key role in eliminating HBV, and it is expected to achieve the functional cure of CHB by rebuilding the patient’s adaptive immunity. Great progress has been made in therapeutic vaccines, cellular immunotherapy, immune checkpoint blockade, T cell metabolic reprogramming, and strategies of neutralizing antibody targeting adaptive immunity for the treatment of hepatitis B. This article summarizes the above-mentioned therapies for hepatitis B in recent years.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Clinical Hepatology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS